Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

@article{Leprtre2012ExcessMA,
  title={Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.},
  author={St{\'e}phane Lepr{\^e}tre and Th{\'e}r{\`e}se Aurran and B{\'e}atrice Mah{\'e} and Bruno Cazin and Olivier Tournilhac and Herv{\'e} Maisonneuve and Olivier Casasnovas and Alain Delmer and V{\'e}ronique Leblond and Bruno Royer and Bernadette Corront and Sylvie Chevret and Roselyne Del{\'e}pine and Sandrine Vaudaux and Eric Van Den Neste and Marie Christine B{\'e}n{\'e} and R{\'e}mi Letestu and Florence Cymbalista and Pierre Feugier},
  journal={Blood},
  year={2012},
  volume={119 22},
  pages={5104-10}
}
A French and Belgian multicenter phase 3 trial was conducted in medically fit patients with untreated chronic lymphocytic leukemia. Of 178 patients enrolled in the study, 165 were randomly assigned to receive 6 courses of oral fludarabine and cyclophosphamide (FC) in combination with rituximab (FCR; 375 mg/m(2) in cycle one, 500 mg/m(2) in all subsequent cycles) or alemtuzumab (FCCam; 30 mg subcutaneously injected on cycle days 1-3); each cycle was 28 days. Recruitment was halted prematurely… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Similar Papers

Loading similar papers…